Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Cash & Equivalents (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Cash & Equivalents for 13 consecutive years, with $681480.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 174.37% year-over-year to $681480.0, compared with a TTM value of $681480.0 through Dec 2025, up 174.37%, and an annual FY2025 reading of $681480.0, up 174.37% over the prior year.
  • Cash & Equivalents was $681480.0 for Q4 2025 at Abvc Biopharma, up from $192068.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $6.6 million in Q4 2021 and bottomed at $60155.0 in Q4 2023.
  • Average Cash & Equivalents over 5 years is $1.2 million, with a median of $685056.5 recorded in 2022.
  • The sharpest move saw Cash & Equivalents skyrocketed 801.61% in 2021, then crashed 95.68% in 2023.
  • Year by year, Cash & Equivalents stood at $6.6 million in 2021, then crashed by 78.8% to $1.4 million in 2022, then plummeted by 95.68% to $60155.0 in 2023, then skyrocketed by 312.9% to $248382.0 in 2024, then surged by 174.37% to $681480.0 in 2025.
  • Business Quant data shows Cash & Equivalents for ABVC at $681480.0 in Q4 2025, $192068.0 in Q3 2025, and $388251.0 in Q2 2025.